Stanford, CANCT03909282Now EnrollingIRB Ready

Ductal Breast Carcinoma in Situ Clinical Trial in Stanford, CA

Access cutting-edge ductal breast carcinoma in situ treatment through this clinical trial at a research site in Stanford. Study-provided care at no cost to qualified participants.

Sponsored by Stanford University

Quick Self-Assessment

See if you qualify for this Stanford location

Preparing your pre-screening questions…

Expert Care in Stanford

Access ductal breast carcinoma in situ specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related ductal breast carcinoma in situ treatment provided free

Apply for This Stanford Location

Check if you qualify for this ductal breast carcinoma in situ clinical trial in Stanford, CA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Stanford

    Convenient for CA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Stanford site if eligible
  4. 4Begin participation

About This Ductal Breast Carcinoma in Situ Study in Stanford

The purpose of this pilot study is to compare by pathological findings surgical excision versus neoadjuvant radiotherapy followed by delayed surgical excision of ductal carcinoma in situ (DCIS)

Sponsor: Stanford University

Who Can Participate

Inclusion Criteria

Core needle biopsy demonstrating DCIS (ductal carcinoma in situ) of non-palpable, image-detected breast abnormality
Signed and dated IRB-approved written informed consent
Women 18 years of age or older
Mammographic calcifications or MRI non-mass enhancement measuring 4 cm or less in greatest dimension, including multifocal disease
Estrogen receptor positive or negative, progesterone receptor positive, negative or unknown; HER2 positive, negative or unknown DCIS is allowed
Diagnostic needle biopsy within 16 weeks of randomization
Patients must have a biopsy marker placed within the tumor bed confirmed on post biopsy imaging.
Placement of Savi scout optical reflectance marker in tumor bed area as a wireless guide for surgery and for neoRT treatment planning is preferred but not required if anatomic metallic markers are sufficient for radiation planning. Placement does not have to occur before randomization. Additionally, wire localization before surgery is permissible.
Planned lumpectomy. Mastectomy will be acceptable if lumpectomy fails by virtue of involved margins or size of lesion, or patient chooses this approach after randomization
Radiation Oncologist to ascertain feasibility of PBI prior to randomization - based on their estimation that 30% or less of the breast volume will be encompassed in the radiation fields
Patients who had a prior contralateral invasive or non-invasive (DCIS) cancer are eligible
ECOG performance status 0, 1, or 2
Concurrent foci of atypia or lobular carcinoma in situ in the ipsilateral or contralateral breast are allowed

Exclusion Criteria

Invasive carcinoma on core needle biopsy, including microinvasive carcinoma
Radiographic extent of DCIS \>4.0 cm
Mass lesion on breast imaging or palpable tumor
No residual radiographic lesion after diagnostic percutaneous core needle biopsy
Prior history of ipsilateral invasive or noninvasive breast cancer
Pregnant or breastfeeding
Prior ipsilateral breast or chest irradiation
Multicentric or multifocal DCIS, if extent is \> 4cm
Synchronous contralateral invasive or noninvasive breast cancer
Pagets' disease of the breast
Active collagen vascular disease
Positive axillary lymph nodes
Not meeting the described criteria for partial breast irradiation during initial clinical evaluation.
Psychiatric or addictive disorders or other condition, that, in the opinion of the investigator, would preclude the patient from meeting the study requirements or interfere with the interpretation of study results
Endocrine therapy is not allowed from the time of study randomization to the completion of surgery unless the endocrine therapy is being continued for a contralateral cancer

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Stanford?

Yes, this clinical trial (NCT03909282) has an active research site in Stanford, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Ductal Breast Carcinoma in Situ Treatment Options in Stanford, CA

If you're searching for ductal breast carcinoma in situ treatment options in Stanford, CA, this clinical trial (NCT03909282) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Stanford research site is actively enrolling participants for this clinical trial. You'll receive care from experienced ductal breast carcinoma in situ specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all ductal breast carcinoma in situ clinical trials near you to find additional studies recruiting in your area.

More Breast Cancer Trials in Stanford, CA

See all breast cancer clinical trials recruiting in Stanford — not just this study.

Browse Breast Cancer Trials in Stanford →

Browse More Trials by Condition

Breast Cancer TrialsUlcerative Colitis TrialsAnkylosing Spondylitis TrialsAll Conditions →

Ready to Join in Stanford?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Stanford, CA